复发或难治性多发性骨髓瘤患者且符合B细胞成熟抗原靶向治疗条件者的疾病负担
Burden of illness among patients with relapsed or refractory multiple myeloma, and eligible for B-cell maturation antigen-targeted therapies.
作者信息
Giri Smith, Lin Dee, Dixon Ruth Wangia, Kim Nina, Fowler Jessica, Barron John, Tan Hiangkiat, Nguyen Chi, Asefaha Feven, Vojjala Shiva, Min Elissa E, Wu Bingcao
机构信息
Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.
O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA.
出版信息
Future Oncol. 2025 Jul;21(17):2155-2165. doi: 10.1080/14796694.2025.2514399. Epub 2025 Jun 5.
BACKGROUND
B-cell maturation antigen (BCMA)-targeted therapies were approved for triple-class exposed relapsed/refractory multiple myeloma (RRMM) after ≥4 lines of therapy.
METHODS
This claims-based retrospective analysis examined clinical and economic burden among United States patients who met eligibility for BCMA-targeted therapies and started a new therapy between 1 January 2016 and 30 September 2022.
RESULTS
Of 228 eligible patients (median age: 64, 52.6% male, 68.7% White), clinical burden was characterized by prevalent MM-related conditions and complications, and high treatment failure rate (44.7% in 6 months). Hospitalization rate increased from 48.3% to 71.1%, while healthcare costs per-member-per-month increased from $35,964 during 12-month baseline to $41,358 during follow-up (median: 11.8 months).
CONCLUSIONS
Patients with heavily pre-treated RRMM endure high disease burden and could benefit from novel therapies.
背景
B细胞成熟抗原（BCMA）靶向疗法在≥4线治疗后被批准用于接受过三类药物治疗的复发/难治性多发性骨髓瘤（RRMM）。
方法
这项基于索赔的回顾性分析研究了符合BCMA靶向疗法资格且在2016年1月1日至2022年9月30日期间开始新治疗的美国患者的临床和经济负担。
结果
在228名符合条件的患者中（中位年龄：64岁，52.6%为男性，68.7%为白人），临床负担表现为普遍存在的与MM相关的病症和并发症，以及高治疗失败率（6个月内为44.7%）。住院率从48.3%升至71.1%，而每人每月的医疗费用从12个月基线期的35,964美元增至随访期间的41,358美元（中位值：11.8个月）。
结论
接受过大量前期治疗的RRMM患者承受着较高的疾病负担，可能从新型疗法中获益。
Zotero 插件